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8ABSTRACT
Based on Finnish twin studies, genetic effect on asthma and atopy has been estimated to
be 35 % - 87 %. For a genetic study on atopy and asthma, self-reported asthma patients
and their family members (1015 individuals) were ascertained in the Kainuu province,
representing a Finnish founder population. Founder populations like this have been
suggested as ideal when studying genetic susceptibility to complex disorders.
Phenotyping was done with questionnaires, interviews, evaluation of the medical records
with patients’ permission, and serum total IgE and allergy screening test measurements.
401 self-reported asthma patients were confirmed to have asthma according to
information obtained in medical records and granted reimbursement for anti-asthmatic
medication by the Social Insurance Institution. Family members were screened for atopic
and asthmatic symptoms with questionnaires and serum total IgE and allergy screening
test measurements. The self-reported allergic nasal symptoms and self-reported physician
diagnosed rhinitis were then compared with allergy screening test results. Sensitivity and
specificity of both self-reported symptoms and diagnosed rhinitis remained poor and an
objective verification of allergy (high serum total IgE level or positive allergy screening
test) was concluded to be better than self-reported data for the allergic phenotype.
Chromosomal regions 5q31-q33, IL4RA, 19p13 and Xq/YqPAR were studied using
linkage and association analyses. All the linkage analyses remained negative, yet on the
chromosome 19p13, around the FCER2 gene, a six-marker haplotype was found to be
associated with high serum total IgE level (>100 kU/l) and on the chromosome Xq, a
two-marker haplotype was shown to be associated with asthma. In the first analysis on
the chromosome 5q with microsatellites, no significant haplotype association was found,
although there was a clustering of haplotypes around the IL9 gene. When the 5q31-q33
was reanalyzed using SNPs and the Haplotype Pattern Mining method, IL13ex4.1 was
found to be associated with high serum total IgE level. Also, in the IL4RA gene, S411L
was shown to be associated with asthma and, respectively, C406R with high IgE level. In
addition, the CFTR gene was screened for two Finnish major mutations, but because of
the low frequency of the mutations, no conclusions could be made on the association
between the CFTR mutation carriership and asthma. To conclude, we found suggestive
9evidence for the IL4RA gene and the IL13 gene and the FCER2 gene region contribution
to atopy as well as for the IL9RA gene region and the IL4RA gene contribution to
asthma.
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INTRODUCTION
In recent years, the prevalence rates for asthma and atopy have increased in Finland
(Haahtela et al. 1990; Pallasaho et al. 1999; Rimpelä et al. 1995) as well as in other
Western countries (Åberg et al. 1995). In the 1970’s, 5 % of the Finnish population was
estimated to have hay fever and 1 % asthma, while the respective numbers in the 1990’s
were 15 % and 3-5 % (Haahtela et al. 1990). Although the prevalence of asthma has risen
in Finland, it still is somewhat lower than in some Anglo-Saxon countries (Burr et al.
1994; Duffy et al. 1990). The prevalence of hay fever has already been reported to be
higher than, for instance, in Germany (Huovinen et al. 1999; Varjonen et al. 1992; von
Mutius et al. 1994). Vaccinations and lower rates of infectious diseases, such as hepatitis
A or tuberculosis, as a part of higher standard of living and better hygiene, have been
suggested as possible explanations for the increase in atopic diseases (Matricardi et al.
1997; von Hertzen et al. 1999). The concept of genetic susceptibility to asthma is based
on the epidemiological twin and family studies, which have offered evidence for familial
aggregation of asthma and atopy. Among the Finnish twins, estimates of genetic effect on
asthma have varied from 35 % to 87 % (Laitinen et al. 1998; Nieminen et al. 1991), and
on hay fever from 74% to 82 % (Räsänen et al. 1998).
Both a candidate gene based strategy and a genomewide search have been introduced as
methods for studying genetic susceptibility to asthma and also to other multifactorial
diseases. The candidate gene strategy can be used to test a certain hypothesis: Does this
particular genetic variant contribute to genetic susceptibility for asthma or atopy? This
strategy is based on the previous knowledge of biological mechanisms in asthma
(functional candidates) and in asthma-related traits, such as high serum total IgE level.
Another way of studying is a genomewide screening which offers information on
chromosomal regions with previously unknown but possibly important genes (positional
candidates). For asthma and atopy, the inheritance pattern is not known but since they are
common disorders, the susceptibility alleles are accordingly expected to be common in a
given population. However, not all of those with the susceptibility alleles become
affected (reduced penetrance) and not everyone of the affected individuals has the same
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set of susceptibility alleles (genetic heterogeneity or phenocopies) hence making the gene
studies more complex than when studying diseases with Mendelian inheritance.
Until recent years, both functional and positional candidate genes have been studied using
microsatellite markers. The large-scale discovery of single nucleotide polymorphisms
(SNPs) has changed this, because unlike the polymorphic markers, they may also be
located on the coding region of the gene (cSNP), and thus they may change the gene
product and be true disease causing alleles. To find out these DNA variations is one of
the results of the systematic sequencing of the human genome (Human Genome Project).
However, because of the many SNPs needed in the studies, both large-scale genotyping
and statistical methods are required to analyze the results. Also electronical databases
have been developed, since the amount of knowledge and studies of genetics on asthma
and asthma related traits has enormously increased, such as the Asthma & Allergy Gene
Database (Wjst and Immervoll, 1998; http://cooke.gsf.de/) and the Database of Single
Nucleotide Polymorphisms (http://www.ncbi.nlm.nih.gov/SNP/). The ambitious aim of
the asthma gene projects worldwide is to get more information of the pathology of
asthma and, in future, also to utilize the susceptibility genes in diagnostic and therapeutic
applications.
The studies on asthma and atopy susceptibility genes in the Finnish population are
presented here. First, a reliable method of phenotyping the patients for the genetic study
was required. Thus, the value of self-reported physician-diagnosed asthma and the value
of self-reported respiratory allergic symptoms are discussed when they are compared to
the retrospectively collected information in medical records and to the allergy screening
test. Secondly, four studies are shown with linkage and association analyses of candidate
regions in asthma and atopy among Finnish asthma families. The functional candidate
regions include the chromosomal region 5q31-q33 with the cytokine gene cluster, the
IL9RA gene in the pseudoautosomal region on the sex chromosomes, the IL4RA gene on
the chromosome 16 and the FCER2 gene region on the chromosome 19.
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1. REVIEW OF THE LITERATURE
1.1. Definition of asthma
Asthma is characterized as a reversible obstruction of airways causing cough, wheezing,
dyspnea and mucus production. A typical but not specific finding in asthma is the
eosinophilic inflammation in the bronchial mucosa (Laitinen et al. 1985), and often
associating features are bronhcial hyperreactivity (Higgins et al. 1992), sputum
eosinophilia, blood eosinophilia (Bousquet et al. 1990) and a high serum total IgE level
(Burrows et al. 1989). The diagnosis of asthma is based on self-reported symptoms, the
assessment of the patient’s medical history, a clinical examination and a lung function
testing (peak expiratory flow recording, spirometry and unspecific bronchial challenge
testing) to verify reversible airway obstruction. In the diagnosis, skin prick tests, serum
total IgE measurements and blood eosinophilia can be used as additional criteria. The
difficulty with an asthma diagnosis is that there is no single test that would be both
sensitive and specific for asthma (Siersted et al. 1996). Wheezing by auscultation can be
regarded as a sign of bronchial obstruction but it is not sufficient for the diagnosis in
adults. Sputum eosinophilia, or eosinophil cationic protein in sputum (ECP) as well as
bronchial hyperreactivity and detection of exhaled nitric oxide measure bronchial
inflammation (Henriksen et al. 2000, Pizzichini et al. 1997). The study of histological
findings in bronchial biopsies is an invasive method of showing bronchial inflammation
and is not used in a clinical diagnosis, but it may be used for research purposes. In
Finland, the diagnostic procedure of asthma follows international guidelines (Official
Statement of the American Thoracic Society 1987), and a national effort has also been
made to provide all Finnish pulmonologists and primary care physicians with uniform
instructions for diagnosis and treatment (Report of a Working Group 1996).
Although the main principle of the diagnosis, reversible bronchial obstruction, is simple,
the wide spectrum in the difficulty of symptoms and findings still show the diversity of
the disease. The clinical course of asthma varies between individuals and in the same
individual during the time both spontaneously and depending on anti-inflammatory
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treatment. Asthma can also be divided into an intrinsic and extrinsic form of the disease,
the extrinsic being atopic and the intrinsic being the non-atopic asthma. However,
mechanisms of the intrinsic asthma are not well understood.
Asthma is aggregated in families which has raised the concept of inheritant factors
contributing to the disease. Evidence for the genetic effect on asthma has been obtained
with twin studies. The heretability of asthma has been estimated at 87  % in the Finnish
twin study (Laitinen et al. 1998), 75 % in the Norwegian twin study (Harris et al. 1997)
and 60 % in the Australian study (Duffy et al. 1990). Another way of estimating the

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be 5,4 (Laitinen et al. 1998).
However, also environmental factors together with inheritance or even environmental
exposure alone (occupational asthma) are the necessary conditions to get the disease. In
addition to atopy, smoking and infections have been linked with asthma. Maternal
smoking is a known risk factor for asthma in a child (Martinez et al. 1995), and
respiratory infections cause exacerbations of asthma (Grünberg and Sterk, 1999). Yet, the
avoidance of serious infectious diseases through better hygiene and vaccinations has been
suggested as a basis for the increase in atopic diseases (Matricardi et al. 1997; von
Hertzen et al. 1999). Moreover, in young children wheezing with colds is rather common,
and only a part (40 %) of the “ wheezing children” have asthma later in the childhood
(over 6 years of age) (Martinez et al. 1995), which shows that wheezing is not specific for
asthma, or that the course of the disease varies in the same individual in the course of
time.
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1.2. The role of phenotyping in complex diseases
The main initiative of phenotyping in complex disorders is to group similarly affected
individuals together so that the underlying set of susceptibility genes would also be
similar. In asthma, as in other common multifactorial diseases, the phenotype is a broad
one. The spectrum is a continuation from asymptomatic bronchial hyperresponsiveness to
mild asthma-like symptoms, advancing from seasonal to chronic and severe asthma.
Often associating but not totally overlapping intermediate phenotyps are bronchial
hyperresponsiveness (Burrows et al. 1992) and high serum total IgE level (Burrows et al.
1989) which both have widely been used in genetic studies. Narrowing the phenotype
down to an intermediate phenotype has been used to reduce the number of genes
underlying the disease and thus to make the analysis of susceptibility genes to common
diseases more simple (Lander and  Schork 1994). Also, focusing on those with an early
onset of the disease or on those with the most severe disease may be an useful approach
to limit the phenotype when susceptibility genes are mapped.
Figure 1. Corrrelation of asthma, high serum total IgE and bronchial
hyperreactivity.
For genetic studies on atopy and asthma, lung function testing (especially bronchial
hyperreactivity) of the probands has been widely used (Marsh et al. 1994; Meyers et al.
High serum total IgEAsthma
Bronchial hyperreactivity
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1994; Postma et al. 1995) to verify the asthma diagnosis as well as to offer quantitative
traits for phenotyping. However, performing the lung function testing on hundreds of
probands within a genetic study is a financially demanding task, and the use of
questionnaires for a diagnosis would be beneficial. Also, it is known that bronchial
hyperresponsiveness as well as other lung function test results vary in the course of the
time and they are affected by anti-asthmatic (anti-inflammatory) medication (Hopp et al.
1994; Redline et al. 1989; Siersted et al. 1996). While questionnaires for epidemiologic
studies were developed and validated, self-reported physician diagnosed asthma was
found to be more specific than self-reported asthma (Toren et al. 1993), and this results
has accordingly been used to avoid false positives. Discordance between self-reported
questionnaire data and objective test results favoring false positives has been reported
(Kesten et al. 1997), thus leading to an emphasis on the need for lung function testing.
However, contradictory results have also been presented (Barnes et al. 1999) suggesting
the use of questionnaire data alone for phenotyping.
1.3. Studying inheritance in asthma
1.3.1. Modelling the inheritance of asthma and related traits
The inheritance model of asthma is not known, but it has been studied using the
segregation analysis method where different inheritance models are matched with the
data (Martinez et al. 1997). There is some evidence for inheritance of asthma being either
oligogenic and including a recessive component or being polygenic (Holberg et al. 1996),
but also other inheritance patterns have been suggested (Los et al. 1999). The inheritance
of lung function (FEV1) has been reported to be different in families with asthmatic
family members from that in families without asthmatic individuals. In asthma families,
the polygenic inheritance with a weak recessive component or with common
environmental factors has been suggested, whereas in families without asthma polygenic
inheritance has been considered (Holberg et al. 1998). A maternal effect, either a
maternal genetic effect or environmentally mediated maternal influence, has also been
shown in asthma families. Segregation analyses have also been made on serum total IgE
16
levels leading to contradictory results. Recessive inheritance of low levels as well as of
high levels have been proposed, codominant and polygenic inheritance has also been
suggested and codominant autosomal inheritance of high IgE level (Los et al. 1999;
Martinez et al. 1994).
These segregation analyses clearly demonstrate the complexity of the genetic effect on
multifactorial diseases. The same phenotype may result from a different set of genes
(genetic heterogeneity) or from environmental exposure (phenocopies). Also, only a part
of those with the susceptibility alleles get the disease (reduced penetrance). This is
contradictory to mendelially inherited diseases where the cut-off point for the affected
phenotype usually is more clear and the underlying genotype can be more easily
predicted than in complex diseases.
1.3.2. Mapping susceptibility genes
Two strategies have been used when susceptibility genes of asthma have been mapped: A
candidate gene approach and genomewide searches. In the first one, previous knowledge
of molecules involved in asthma has been used to study appropriate candidate gene
regions. The second one is a method where the whole genome is scanned with an evenly
distributed set of markers. In both strategies, linkage is measured by coinheritance of
alleles at a marker locus with a disease in pedigrees. Linkage can be analyzed either as
non-parametric without a specific inheritance model or as parametric, using the best-
fitting model of segregation analysis. Also, the affected sib pair method can be used
where the proportion of shared gene alleles between sibs is calculated when the expected
shared proportion is 50 %. All these methods need family data, but susceptibility genes
can also be studied by an association analysis using only cases and controls. However,
the association can also be analyzed in family data using disease-associated and control
chromosomes. Another method of using families is the transmission disequilibrium test
(TDT) representing a method which is a combination of association and linkage analysis.
The TDT studies a transmission distortion of alleles that are transmitted to an affected
child from unaffected parents when compared with untransmitted alleles.
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Linkage disequilibrium is a transmission distortion between two chromosomal loci. In
isolated young populations, the intervals of linkage disequilibrium are longer than in
mixed populations, which has been considered an advantage when disease genes are
mapped. Thus, the linkage between the disease and the underlying gene region can be
distinguished with a more sparse marker map, and also in haplotype association analyses
the haplotype spanning the searched gene extends further in isolated populations than in
mixed ones.
Gene mapping studies have previously been made with microsatellite markers but
recently more attention has been given to single nucleotide polymorphisms (SNPs).
SNPs occur in the DNA approximately at frequency of 1 in 350 base pairs, and some of
the SNPs have been hypothesized to act as the predisposing genetic variations to common
diseases (Cargill et al. 1999). SNPs may be located on coding gene regions, and they may
intrinsically represent the predisposing factor or they may be in linkage disequilibrium
with the actual predisposing gene allele.  Microsatellite markers are either intronically
situated or positioned on other uncoding genomic region, and they are in linkage
disequilibirium with the predisposing gene alleles. Another factor favouring the use of
SNPs is the improved technology for genotyping that makes large-scale screening
possible (length-multiplex single-base extension, LM-SBE) (Lindblad-Toh et al. 2000). A
Japanese study offers an example of screening of SNPs in multiple candidate genes in
asthma (Unoki et al. 2000): 29 genes were screened for sequence variations, 33 SNPs
were found in 14 genes, other genes being non-polymorphic, and the tromboxane A2
receptor gene was reported to associate with asthma. Also, the study showed the large
variation in the density of SNPs, since there were several genes without alterations, and
in genes, where the SNPs were found, the densities varied from 1/73 bp to 1/1842 bp.
1.3.3. Animal models and the use of monogenic diseases
In addition to the study of linkage or association in humans, it is also possible to carry out
candidate gene studies and genome screens in mice, and because of the great homology
of the human and murine genomes the results of animal studies can be utilized in human
research. Inbred mice strains have been used to study genetically determined
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characteristics such as bronhcial hyperresponsivenss (Nicolaides et al. 1997), and
transgenic and knock-out murine models have been especially useful for clarifying the
gain of function (or loss of function) of a single gene. One example is a prostaglandin
receptor (DP) deficient mice model which offers evidence for the importance of the
prostaglandin pathway in asthma. Prostaglandin D2 is produced by mast cells, and it is
involved in bronchial smooth muscle constriction, mediating its effect through the
prostaglandin receptor. The DP deficient mice have been reported to have similar serum
IgE levels as the wild-type mice (Matsuoka et al. 2000). However, the DP deficient mice
do not to develop airway hyperreactivity and eosinophilia in response to antigen
challenge, and they also have lower levels of Th2 type cytokines such as IL4, IL5 and
IL13 in response to an antigen challenge than the wild-type mice. The IL4 and IL4Rα,
IL5 and FcεRII deficient mice have also been studied as experimental asthma models:
The airway responsiveness of the IL4 deficient and the IL5 deficient mice after the OVA
sensitization and challenge was lower than in the sensitized wild-type mice and
comparable to the non-sensitized wild-type mice (Hamelmann et. al 2000). In addition,
IL13 and IL4Rα have been found to contribute to bronchial hyperreactivity according to
Grünig et al. (1998) as well as IL9 (Nicolaides et al. 1997). Fc%&''
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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have higher IgE levels after immunization than the wild-type mice (Yu et al. 1994).
Lastly, monogenic diseases may offer information of molecular mechanisms involved as
well in complex disorders. Autosomally dominantly inherited familial eosinophilia has
been mapped to the chromosomal region 5q31-q33 (Rioux et al. 1998). This could be
considered as a suggestive finding also for other eosinophilic disorders such as asthma,
which is associated with blood eosinophilia and eosinophilic inflammation in bronchial
mucosa. In the same year, Martinez et al. reported a linkage between circulating
eosinophils and the chromosomal region 5q31-q33 (1998).  Likewise, hyper-IgE
syndrome (Job’s syndrome) has been applied as a simplified model of other IgE defects
such as atopy. However, findings of the IL4RA SNP (Q576R) in hyper-IgE are
contradictory and thus only of limited use in the study of atopy (Grimbacher et al. 1998,
Hersey et al. 1997).
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1.4. Candidate genes - the immunologic basis and previous genetic studies
The search for the candidate genes of asthma is based on the knowledge of biological
mechanisms (functional candidate genes) underlying and correlating to asthma such as
inflammation on bronchial mucosa (Laitinen et al. 1985), bronchial hyperresponsiveness
and high serum total immunoglobulin E (IgE) level. Even though many molecules and
biological pathways are known to be important in allergic inflammation, it is not known
whether there are variations in corresponding genes that would predispose to asthma. For
example, the accumulation of eosinophils on bronchial mucosa is a typical for asthma,
and especially IL5 stimulates differentation and proliferation of eosinophils, which has
made the IL5 signaling important in asthma. Other T-helper2-type cytokines, such as IL4
and IL13, activate B-cells to produce antigen-specific IgE which is then bound by high
affinity receptors (FcεRI) on mast cells. This binding of IgE by FcεRI receptors leads to
the degranulation of mast cells and to the release of histamine which is known to cause
bronchial obstruction and mucus production and finally leading to symptoms of asthma.
Genes for these molecules among others involved in allergic inflammation have been
studied as candidate genes for asthma and atopy.
The chromosomal regions 5q and 11q were the first two regions to be studied as
candidate gene regions in asthma and atopy (Cookson et al. 1992; Marsh et al. 1994;
Meyers et al. 1994). The chromosome 5q includes an interleukin gene cluster (IL3, IL4,
IL5, IL9, IL13), a granulocyte-macrophage colony stimulating factor (GM-CSF) gene, an
interferon regulatory factor (IRF1) gene, a fibroblast growth factor acidic (FGFA) gene
and a β2-adrenergic receptor gene, and the chromosome 11q includes e.g. a gene for the
high affinity receptor for IgE (FCER1), all of which are considered to have an effect on
the asthmatic phenotype. The 5q region has been studied in respect to different
phenotypes such as asthma, bronchial hyperresponsiveness (BHR) (Postma et al. 1995),
high serum total IgE level (Meyers et al. 1994, Marsh et al. 1994), circulating eosinophils
(Martinez et al. 1998) and using different populations. Populations have varied from
isolated Caucasians to populations with a different ethnic origin such as Japanese and
African Americans (Noguchi et al. 1997, Hizawa et al. 1998). In addition to the mapping
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of circulating eosinophil levels (sib pairs concordant for low levels of eosinophils, <2 %)
to the chromosomal region 5q, autosomally dominantly inherited familial eosinophilia
has also been mapped on 5q31-q33 (Martinez et al. 1998; Rioux et al. 1998) in a
genomewide search. Both the association (Doull et al. 1996) and the linkage analysis
(Marsh et al. 1994) have been used, as well as the SNPs (Hopes et al. 1998), in addition
to microsatellite markers. The majority of the studies have yielded some evidence for the
region 5q having asthma and atopy susceptibility genes, while only few have reported
contradictory results (Kamitani et al. 1997) (Table 1). One of the latest 5q31-q33 studies
is a retrospective analysis of the region using 11 study samples by the Consortium on
Asthma Genetics (COAG) (Lonjou et al. 2000). In this retrospective collaboration study,
evidence was found for susceptibility genes for asthma but not for atopy.
1.4.1. IL4 and IL4RA genes
Interleukin 4 is probably the strongest candidate of the 5q cytokines for the contribution
to asthma and atopy. Interleukin 4 (IL4) is needed in the differentation from T-helper-0
(Th0) cells into T-helper-2-type (Th2) which are capable of producing more cytokines,
finally leading to an allergic inflammation of the bronchial epithelium. IL4 is also known
to stimulate differentation and proliferation of the B cells, IgE production, MCH class II
antigen expression, proliferation of human mast cells and expression of FcεRI and FcεRII
(Chomarat and  Banchereau 1997). The effect of IL4 is mediated through its receptor
which is a heterodimer consisting of two chains: A common γ-chain which is shared by
	 	!')')*')+'),')-."')*&/
	')*')*&/		
-*0 1(Chomarat and
Banchereau 1997) and also able to transduct signals of IL13 by a heterodimer formed by
')*&/')-.&/(Izuhara and  Shirakawa 1999). Strong evidence for the
importance of the IL4 pathway in asthma has been obtained from an animal model where
the administration of either IL4 or IL13 induced the asthma phenotype to wild type mice
(Grünig et al. 1998). However, neither of the cytokines was able to induce the asthma
#')*&/
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in the signalling by IL4 (and IL13). Eight SNPs leading to an altered gene product have
been reported in the IL4RA (Deichmann et al. 1997; Hershey et al. 1997; Ober et al.
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2000), of which Q576R and I50V have been reported to associate with atopy (Hershey et
al. 1997; Mitsuyasu et al. 1998). Using an in vitro'0
')*&/
was shown to upregulate the receptor response to the IL4 in the cell lines, thus providing
supporting data on functional effects of the polymorphism. Although Mitsuyasu et al.
found evidence for IL4RA gene contribution to atopy in Japanese, in another study
among the Japanese population, no association between the IL4RA (Q576R) and atopy or
asthma was found (Noguchi et al. 1999).
1.4.2. IL9 and IL9RA genes
Interleukin 9 is one of the 5q cytokines and known to affect differentation and
proliferation of mast cells, proliferation of T cells, IgE production by B cells (together
')*"&2$3		
/
εRI (Demoulin and Renauld
1998). Indeed, a reduced expression of the IL9 gene has been found in the lung tissue of a
hyporesponsive mouse strain (Nicolaides et al. 1997). In humans, the expression of IL9
mRNA is increased in asthmatic individuals compared to atopic and non-atopic control
individuals (Shimbara et al. 2000), and the IL9R immunoreactivity is also higher in
asthmatic than in control individuals. The other part of the IL9 pathway is IL9R, which is
	
	4$	
'),&/γ-chain. The IL9RA
	/			(320 kb) in
the long arms of the X and Y chromosomes (Kermouni et al. 1995) and also expressed by
both chromosomes (Vermeesch et al. 1997). Holroyd et al. found linkage between this
pseudoautosomal region and asthma or bronchial hyperreactivity in Italians (Holroyd et
al. 1998).
1.4.3. Studies of other genes on 5q31-q33
Although the cytokine gene cluster has been an obvious candidate through the effect of
the cytokines on IgE and eosinophil production, the β2-adrenoreceptor (ADBR2) gene
and the leucotrien C4 synthase (LTC4S) gene (Table 1), locating telomeric from the
cytokine gene cluster, have also been studied on the chromosome five. The ADBR2 gene
is an important candidate gene in asthma, since the receptor is involved in smooth muscle
relaxation which is caused by endogenous or exogenous agonists. Four coding
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polymorphisms (R16G, Q27E, V34M and T164I) and linkage disequilibrium between the
first two ones have been reported in the gene. The first two amino acid variations are
located extracellularly and the last two are found in the transmembrane region of the
receptor (Liggett 1997; Reihsaus et al. 1993). The similar distribution of polymorphisms
reported in asthma and control groups exclude the SNPs as a cause for asthma (Reihsaus
et al. 1993). However, the SNPs have been suggested to explain variations in asthma
phenotype, such as the response to bronchodilators (Martinez et al. 1997) or nocturnal
asthma (Turki et al. 1995). Moreover, in vitro studies have shown enhanced
downregulation of the G16 variant and resistance to the downregulation of the E27
variant of the receptor (Liggett 1997).
Other candidate genes on 5q31-q33 include genes for IL5, GM-CSF, CD14 and IRF1 of
which the cytokine IL5 is known to act on the growth and differentiation of eosinophils.
In an animal model, the IL5 deficient mice did not develop increased bronchial
hyperreactivity in response to sensitization and an airway challenge with ovalbumin
(Hamelmann et al. 2000). In addition, there was no accumulation of eosinophils in the
bronchial mucosa in the IL5 deficient mice, which demonstrates the importance of IL5
both in aggregation of eosinophils and in bronchial hyperreactivity. Still, as 30 atopic and
30 control individuals were screened for sequence variations in the IL5 gene and in the
IL5RA gene, no polymorphisms were detected in the coding regions or in the promoter of
the IL5 gene, which suggests that the alterations in the IL5/ IL5RA genes would not
explain the genetic susceptibility to asthma or atopy in humans (Pereira et al. 1998). GM-
CSF has been explained to have an effect on migration of eosinophils into the tissues. As
variations were searched for in the GM-CSF gene, an I117T polymorphism was found to
be associated with asthma and bronchial hyperreactivity in a Swiss asthma study
(Rohrbach et al. 1999). Another two genes on 5q31-q33 that affect the Th1/Th2 balance
are the genes for CD14 and IRF1. CD14 functions as a receptor on monocytes,
macrophages and is also found as a soluble form, and it binds bacterial antigens favouring
differentation of lymphocytes into Th1 type. An SNP in the promoter of the CD14 gene
has been reported to associate with serum total IgE level (Baldini et al. 1999). Also a
study on knock-out mice of IRF1 gene showed an altered cytokine production with higher
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levels of Th2 type cytokines such as IL3, IL4, IL5 and IL6, and respectively, lower levels
of IFNγ and IL2 emphasizing the role of IRF1 in the polarization of Th1/Th2 cells and
thus in atopic disorders (McElligott et al. 1997). However, in a Japanese study, the IRF1
gene was screened for polymorphisms, but no coding variants were found, and no
association of the three found non-coding polymorphisms with asthma or atopy was
detected (Noguchi et al. 2000).
1.4.4. High and low affinity receptor for Immunoglobulin E
Th2 type cytokines lead to the production of Immunoglobulin E, which then functions via
high and low affinity receptors, the former being located on mast cells and on basophils,
the latter being located on B- and T-lymphocytes, eosinophils, Langerhans cells etc. The
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leads to the degranulation of mediators such as histamine. The high-affinity receptor for
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in two forms (T-cell- and B-cell-derived) and also as a soluble factor (Delespesse et al.
1989)%&''	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'(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in negative feedback of IgE formation, since the IgE levels were twofold higher in the
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Figure 1. Map of the chromosomal region 5q31-q33
<1 Mb 1-2 Mb ≈2 Mb >2 Mb0.5 Mb
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be considered as candidate genes for susceptibility to asthma and atopy. Cookson et al.
found an association between the maternal inheritance of FCER1B gene alleles and the
IgE responsiveness and later particularly with the I181L polymorphism of the gene
(Cookson et al. 1992; Shirakawa et al. 1994). However, contradictory results exist
(Amelung et al. 1998).
1.4.5. CFTR carriership and asthma
The carriership of mutations of the cystic fibrosis transmembrane conductance regulator
(CFTR) gene has been reported to associate with asthma (Dahl et al. 1998) but,
	#6		708	
asthma (Schroeder et al. 1995). The CFTR is a chloride channel and found e.g. in the
bronchial epithelium in addition to sweat glands; an individual homozygous for a CFTR
gene mutation has either cystic fibrosis with emphysema and bronchiectasiae and
pancreas insufficiency or congenital bilateral absence of the vas deferens (CBAVD). Not
only mutations but also the polymorphisms of the gene (M470V) have been reported to
affect the function of the protein: the M470 variation has been indicated to have a greater
chloride channel activity than the V470 variation (Cuppens et al. 1998). Furthermore, the
number of thymidines (5, 7 or 9) in the intron 8 of the CFTR gene has an effect on the
exon 9 splicing which in turn has an effect on protein function. This 5T allele has been
associated with asthma-like symptoms in addition to CBAVD (Kerem et al. 1997). A
combination of a CFTR mutation and the M470 allele has also been suggested to have
influence on asthma susceptibility (Lazaro et al. 1999)
1.4.6. Other functional candidate genes
Other possible candidate genes include the HLA-area on the chromosome 6p, since the
HLA class II antigens are important in (exogenous) antigen presentation and antigen
specific IgE production (cognate IgE production). Data of the study concerning soybean
epidemic asthma patients in Spain support the hypothesis that the specific HLA alleles
would predispose to asthma (Soriano et al. 1997). This Spanish study population offers a
possibility to examine if genes as susceptibility factors together with specific
environmental exposure can cause a disease.
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Anti-inflammatory cytokines such as interleukin 10 (IL10) and transforming growth
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inhibit the IL4 and IL5 production by Th2 cells, but contradictorily, IL10 stimulates B
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inhibits mast cell proliferation and induces an apoptosis of eosinophils. However, in the
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the remodelling of airways in chronic asthma. Promoter polymorphisms of the IL10 gene
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associate with high serum total IgE level in the Jewish population (Hobbs et al. 1998).
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thus it also has an inhibitory effect on the Th2 cell differentation and on the IgE synthesis
by B cells. In vitro	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stimulated cell cultures is negatively correlated to serum total IgE levels of atopic and
control individuals (Teramoto et al. 1998). Barnes et al. reported linkage between asthma
and 12q15-q24 as well as linkage between serum total IgE level and the same region
(1996):		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exons were screened for polymorphisms in two populations (265 Australian and
Venezuelan individuals), no sequence variations were found (Hayden et al. 1997).
Another candidate on the chromosome 12 is the nitric oxide synthase 1 (NOS1) gene. An
increased synthesis of nitric oxide has been connected with asthmatic inflammation on
bronchial mucosa, and non-invasive methods for measuring the amount of exhaled nitric
oxide have been developed. Nitric oxide is formed by constitutive and inducible nitric
oxide synthase (cNOS and iNOS, respectively) and of these the cNOS is considered to be
involved in vasodilatation and bronchodilatation (Barnes and Liew 1995).
Proinflammatory cytokines, such as IFN-γ, can induce the production of NO by the iNOS
in macrophages and epithelial cells. Interestingly, the IRF1 gene knock-out mice were not
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IRF1 response elements were identified in the iNOS promoter in mice (Kamijo et al.
1994), which emphasizes the role of IRF1 in the iNOS gene induction.
Another example of other candidates is the gene for the Clara cell scretory protein (CC16,
previously CC10) on the chromosome 11q13. The CC16 is a product of nonciliated
respiratory tract cells (Singh et al. 1988) and it can be detected in the bronchoalveolar

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activity (Dierynck et al. 1995) and thus has anti-inflammatory properties. A
polymorphism of the CC16 gene (38A>"			
asthma and lower plasma CC16 levels (Laing et al. 2000), although the functional effects
of the 38A>	#			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
of the CC16 gene. In another study, no association was found between the CC16 gene
and atopy or asthma (Campbell DA et al. 1996).
1.4. Genomewide searches
In addition to the candidate gene strategy, genomewide searches have been used to study
asthma and atopy susceptibility genes. With this method, using markers evenly spaced
across the whole genome, novel loci involved in the genetic susceptibility of the disease
can be identified (positional candidate gene regions). It has been considered that a
chromosomal location or a SNP associated with a trait in more than one study population
would strengthen the results: A region associating with a disease in several studies would
include a susceptibility gene more likely than if a locus was found to be associated in
only one population. Several genome scans have been published, the first one by Daniels
et al. (1996). These scans have been made using several asthma associated phenotypes
such as serum total IgE level, BHR, eosinophil count, specifig IgE responsiveness, PEF
variation, symptoms and mite-sensitive atopic asthma; and several chromosomal loci
have been reported to be linked with these phenotypes (Daniels et al. 1996; CSGA 1997;
Malerba et al. 1999; Wjst et al. 1999, Ober et al. 2000) (Tables 2 and 3). As in the
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candidate gene studies, the results have varied in different populations reflecting the
heterogeneity of the studied populations, the complexity of the disease and the difference
between used phenotypes. Also, the most studied candidate gene region, the 5q, has been
identified in three of the genomewide searches with phenotypes for asthma, mite-
sensitive atopic asthma and logarithm of serum total IgE (Ober et al. 2000, Yokouchi et
al. 2000 and Xu et al. 2000). The chromosomal region 16p has been reported with one
scan (Ober et al. 2000), the region Xq with one (Wjst et al. 1999), and the region 19p has
not been found in any of the genome scans. The most often found regions (5/8) in the
genomewide searches are 2q, 6p (including e.g. the HLA area) and 12q (including e.g. the
'29"
1.6. Advantages of a founder population in gene mapping studies
As previously explained, the power of the genetic study of complex diseases can be
increased by limiting the phenotype. Another factor affecting the power of the study is
the appropriate study population. Founder populations and small stable populations,
inbred ones, and geographically localized populations have been suggested as an optimal
choice (Wright et al. 1999). A more consistent environment as well as more uniform
genetic backround underlying the disease make isolated populations ideal for studying
multifactorial diseases. Hence, the number of loci/genes affecting the disease is expected
to be lower (reduced genetic heterogeneity). In addition, longer segments of
chromosomes around the disease gene appear identical in disease associated
chromosomes (linkage disequilibrium) in isolated gene pools than in mixed populations.
Indeed, the Finnish population has been used for studies of many multifactorial diseases,
e.g., familial combined hyperlipidemia, schizophrenia, multiple sclerosis and psoriasis
(Asumalahti et al. 2000; Hovatta et al. 1999; Kuokkanen et al. 1997; Pajukanta et al.
1998). In breast and ovarian cancer (BRCA1 and BRCA2 carriers), the extent of LD has
been shown to be 1.6-15.5 cM in the conserved haplotypes of the carriers of the BRCA1
and BRCA2 gene mutations.
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Also, the Finnish population as a whole forms an isolate, which has been confirmed by
molecular genetic studies. Sajantila et el. (1996) have shown the Finns to have
significantly less diversity in the Y chromosomal haplotypes compared to the Saami,
Swedes and Estonians indicating that the number of male founders of the Finns has been
small. The frequency of the “Finnish disease heritage” is also in agreement with the
population history, over 30 rare Mendelian inherited disorders that are typical to Finland
and seldom met in other countries fave been found (de la Chapelle 1993; Peltonen et al.
1999). Likewise, a few other inherited diseases, such as cystic fibrosis, are considerably
less frequently met in Finland than in other countries (Kere et al. 1994), which also
indicates an isolated gene pool of the Finns. Linkage disequilibrium mapping has been
successfully used when the disease genes of the “Finnish heritage” have been mapped.
Already in 22 of the 35 diseases, the disease causing gene has been identified (Peltonen et
al. 1999, Varilo et al. 2000).
In Finland, the population living in the Kainuu province can be regarded as an isolated
subpopulation of the Finns. Kainuu was settled in the sixteenth century mainly by people
from South Savo and the estimated number of founders was low, up to few hundreds
families (Koskinen et al. 1994, de la Chapelle 1993; Peltonen 2000). The castle of
Kajaani was built during the years of 1604-1619, and the town of Kajaani (capital of the
Kainuu province) was founded in 1651 around the castle. After the initial settlement the
immigration rate remained low. Also, the growth of the population started rather slowly,
and it was not until in the 19th century than the total number of the Finnish population
reached the limit of 1,000 000. Now, approximately 5,100 000 inhabitants live in Finland
with 1.8 % of the population in Kainuu (Finnish Statistics on Medicines, 1996). The
incidence of the congenital chloride diarrhoea being higher in Kainuu than elsewhere in
Finland provides evidence for the isolated character of this subpopulation (Höglund et al.
1995). Also, when congenital chloride diarrhoea was mapped, haplotype analysis
revealed a linkage disequilibrium spanning for 12 cM (Höglund et al. 1995) in the disease
gene carrying chromosomes. Thus, both the molecular genetic studies and the data of the
population history support the designation of the Kainuu population as a founder
population.
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Other isolated populations have also been used for genetic and epidemiologic studies on
asthma and atopy. The Pennsylvania Old Order Amish and Hutterites are religious inbred
isolates living in the USA; the members of both groups live mainly on communal farms
(Marsh et al. 1994, Ober et al. 2000). Only two major mutations of cystic fibrosis have
been found in the Hutterites. The populations on Barbados in the Caribbean Sea and on
Tristan da Cunha in the South Atlantic Ocean are examples of geographical isolates. The
population on Tristan da Cunha is very small (only 300) but with a very high frequency
of asthma (23 % of the population has definite asthma) (Zamel et al. 1996). On the island
of Barbados, the asthma prevalence is 13 % and the size of the population is 250 000.
With this Afro-Caribbean population, a linkage between asthma and total serum IgE and
chromosomal region 12q15-q24 has been reported (Barnes et al. 1996).
1.7. Optimizing the likelihood for finding a susceptibility gene in complex disorders
Since the inheritant component of multifactorial diseases is complex and difficult to
determine, the power for gene-mapping study can be optimized by focusing on the
appropriate phenotype, by choosing an optimal study population and by creating suitable
family structures (Lander and Schork 1994). In multifactorial diseases the phenotype is
typically a broad one, and by limiting the phenotype to those with an early onset of the
disease or to those with the most severe disease, the underlying genetic effect is
considered to be stronger than among the individuals with a late-onset or mild disease.
Also by narrowing the phenotype down to those with some intermediate phenotype, the
number of susceptibility genes can be restricted. A young isolate may often be regarded
as an optimal study population and not only because of the wider intervals of linkage
disequilibrium and less genetic heterogeneity but also because of a more uniform
environment and culture (Peltonen et al. 2000). What kind of family structures are best
suitable for the study depends on the preferred statistical approach. If linkage analysis is
used, large pedigrees with several affected individuals are optimal and if association
analysis is used, multiple nuclear families are favored.
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2. AIMS OF THE PRESENT STUDY
The aims of the present studies were to study the possibility if selected biological
candidate gene regions would act as genetic regulators, increasing the susceptibility to
asthma and atopy in the Finnish population, as well as to find reliable methods for
phenotyping a large number of patients for genetic studies on atopy and asthma.
The specific aims were:
2.1. In the linkage and association analyses, the aim was to study the possibility whether
the following chromosomal regions contribute to asthma and atopy among the Finnish
asthma families:
5q31-q33
IL4RA gene on 16p12
IL9RA gene region on Xq/Yq PAR
FCER2 gene region on 19p13.
2.2. To study the supposition whether self-reported physician-diagnosed asthma could be
used as an inclusion criterium, and to study the possibility if self-reported respiratory
allergic symptoms could be used alone without allergy testing when phenotyping
individuals for a genetic study.
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3. MATERIAL AND  METHODS
3.1. Study population
Study families were ascertained through media in Central Eastern Finland (the Kainuu
province) in two batches in November 1994 and in November 1996. The selection criteria
for a proband were: the self-reported asthma diagnosed by a physician, the parents and/ or
grandparents born in Kainuu and the nuclear family willing to participate (proband -
spouse - at least one child, or proband - mother - father, or proband - one of the parents -
at least one sibling). Additional affected family members (uncles, aunts, grandparents,
cousins, further sibs) were included when available. All participants signed an informed
consent where they gave a permission to use their blood samples for a scientific study.
The asthma patients were also inquired in which hospitals they had been diagnosed and
treated, and they were asked for a permission to study their hospital files concerning
asthma and allergy. The National Board of Health confirmed the permission to attain the
access to these patients' medical records. The study was approved by the ethical
committees of the Department of Medical Genetics, University of Helsinki and the
Kainuu Central Hospital.
      Figure 1. The Kainuu province’s geographical reference to Finland and Europe
Kainuu
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Figure 2. Municipalities of the Kainuu province.
3.2. Questionnaires and medical records
Both the asthmatics and their family members filled out a health questionnaire. The
medical records of asthmatics were reviewed separately by two pulmonary physicians
(P.K. and T.L.). The descriptive remarks of the clinical condition and lung function test
results were collected in a structured form. The significance of reversible airway
obstruction was evaluated according to the ATS criteria (Official statement of the
American Thoracic Society 1987) (Study I, Table 1). Those patients, whose lung function
tests had remained nondiagnostic or were insufficiently done or documented at the time
of the diagnosis, were followed through hospital records to get evidence either against or
for an asthma diagnosis. At the same time, other diseases as a possible cause for the
patients’ dyspnea were evaluated.
Suomussalmi
Puolanka
Vaala
Vuoli-
joki
Kajaani
Sotkamo
Kuhmo
Paltamo
 Ristijärvi
Hyrynsalmi
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3.3. Allergy screening and IgE measurements
All participants donated their blood samples. The IgE measurements were made of serum
samples which were stored at - 70 °C and analyzed in two batches in the same laboratory.
From each sample the following parameters were measured: Serum total IgE level
(Diagnostics CAP FEIA, Kabi Pharmacia, Sweden); an allergy screening test with birch,
mugwort, timothy, horse, cat, dog, home dust mite (Dermatophagoides pteronyssinus),
and Cladosporium herbarum mould (Phadiatop, CAP FEIA, Kabi Pharmacia, Sweden)
(Gleeson et al. 1996; Haahtela et al. 1980; Haahtela and  Jaakonmäki 1981; Varjonen et
al. 1992). If the allergy screening was >0.3 kU/L, the levels of specific IgE antibodies
were measured.
3.4. Genotyping
3.4.1. Markers and maps
Both the microsatellite markers and the single nucleotide polymorphisms in coding and
non-coding DNA were used as markers (Table 4). The markers were organized by
different published genetic and physical maps: Marshfield Center for Medical Genetics
(http://research.marshfieldclinic.org/genetics/), Genethon
(http://www.genethon.fr/genethon), the Human Resources in National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov/genome/guide/human/), the
Cooperative Human Linkage Center (http://lpg.nci.nih.gov/CHLC/), Genome Data Base
(http://gdbwww.gdb.org/); and Lawrence Berkeley National Laboratory (http://www-
gsd.lbl.gov/) and Whitehead Institute (http://www-genome.wi.mit.edu/). A physical map
was constructed for fine mapping regions by radiation hybrid mapping when there was no
accurate information of the order of the markers. In the haplotype association analyses it
is essential that the order of the closely located markers is correct and the published maps
usually are rather sparse. In Studies II and IV, the GeneBridge 4 and the Stanford panel
(Research Genetics, Inc., USA) were used for physical mapping, and the scoring results
were analyzed by software (http://www-genome.wi.mit.edu/ or http://www-
shgc.stanford.edu/). Physical maps were then used as a basis for genetic maps, 0,9 Mb
corresponding to roughly 1 cM, although the recombinations do not occur evenly
throughout the genome.
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3.4.2. Genotyping of microsatellite markers
In these studies, the DNA was extracted from blood leukocytes by a standard non-
enzymatic method. The DNA segment under study was amplified exponentially by
polymerase chain reaction (PCR) in the PCR assays containing 50 ng of genomic DNA,
0.2 mM of each primer, 0.3 U of the DNA polymerase (Dynazyme, Finnzymes, Finland)
and 0.2-0.4 mM of each dNTP in a total volume of 20 µl. The PCR products were
electrophoresed on denaturating 7 M urea/ 6 % polyacrylamide gels where the alleles
were distinguished by size and visualized by silver staining.
3.4.3. Genotyping of SNPs by restriction enzyme digestion
In Study V, four SNPs (I50V, E375A, C406A and S761P) of the IL4RA gene were
genotyped with the restriction enzyme digestion method. Each of the polymorphic sites
was amplified by PCR in a total volume of 10 µl with 50 ng of the dried DNA in each.
The amount of the polymerase enzyme (AmpliTaq Gold, Perkin Elmer, New Jersey)
varied from 0.5U (E375A and C406R) to 1.0U (I50V and S761P) per reaction. The
polymorphic sites were cut by restriction enzyme digestion using Aci I (E375A), Tsp45 I
(C406R), Msl I (I50V) or Dde I (S761P) (BioLabs, New England, MA). Finally, the
samples were electrophoresed on an agarose gel where alleles were distinguished by size
and visualized by UV illumination.
3.4.4. Genotyping of SNPs by length-multiplexed single-base extension
The length-multiplexed single-base extension method (LM-SBE) includes the
multiplying of the SNPs by PCR using a primer with a tail of different length, single-base
extension with fluorescently labelled dideoxynucleotide (also called mini sequencing) to
locate and mark the SNP and finally, electrophoresis (Lindblad-Toh et al. 2000). The
SNP alleles can be distinguished by size and different colours of fluorescent dyes. 12
SNPs on the 5q31 (IL4ex1, IL13ex4.1, IL13ex4.2, IL5pro, IRF1pro, CSFenh1, CSFenh2,
CSFex4, IL3, TCF, IL9int4, IL9ex5) and 4 SNPs in the IL4RA gene (S411L, Sil676C/T,
Sil1114T/C, Sil1417G/T) were genotyped with the LM-SBE method. The PCR primers
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were designed as close as possible to the SNP (maximum length 150 bp). The primer
pairs were checked for homology to all amplicons and sorted into pools. In the first
round, 10 ng of the genomic DNA was amplified using a pool of primer pairs (0.1 uM)
and 2.5 units of Amplitaq Gold (Perkin Elmer, NJ). In the second round, a 3 µl aliquot of
the primary amplification product was amplified with biotinylated-T7 and biotinylated-
T3 primers. A 7 µl aliquot of this secondary amplification product was purified from the
unincorporated dNTPs using streptavidin-coated Dynabeads (Dynal, Norway). A
multiplex SBE reaction was then carried out on the purified product using SNP-specific
primers, JOE-ddATP (0.12 M),TAMRA-ddCTP (0.12 M), FAM-ddGTP (0.12 M), ROX-
ddUTP (0.60 M; NEN DuPont) and Thermosequenase (0.5 U; Amersham). The excess
ddNTPs were removed from the SBE products using 96-well gel filtration blocks (Edge
Biosystems) prior to the electrophoresis on the ABI 377 sequencers. The LM-SBE gels
were analyzed using an in-house computer program at the Whitehead Institute/MIT
Center for Genome Research (Lindlad-Toh et al. 2000).
3.4.5. Screening for polymorphisms in the IL9 and FCER2 genes
The IL9 and FCER2 genes were sequenced in selected individuals using the genomic
DNA. The amplicons covered all exons (exons 1-5 in IL9 and exons 1-11 in FCER2
gene) and the exon-intron boundaries. The sequencing was performed with a dye
terminator chemistry using an ABI 373A sequencer (PE Biosystems, Foster City, CA).
The screening for the T113M variant of the IL9 gene was done with the enzyme
restriction digestion Nco I (BioLabs, New England, MA), then the samples were
electrophoresed on an agarose gel and visualized by UV illumination.
3.4.6. Mutation screening
For the del394TT and the ∆508 mutation screening of the CFTR gene, the PCR assays
were carried out with 50 ng of genomic DNA, 0.2 mM of each primer, 0.3 U of DNA
polymerase (Dynazyme, Finnzymes, Finland) and 0.2 mM of each of dNTP in a total
volume of 20 µl. The primer pairs were CTG GAG CCT TCA GAG GGT AAA AT and
CAT GCT TTG ATG ACG CTT CTG TA for the ∆508 mutation, and CCT GGG TTA
ATC TCC TTG GA and ATT CAC CAG ATT TCG TAG TC for the del394TT
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mutation. The enzyme restriction digestion was applied using Hinf I (BioLabs, New
England, MA), then the samples were electrophoresed on polyacrylamide gels and
visualized by silver staining.
3. 5. Statistical analyses and power estimations
3.5.1. Linkage analysis
The linkage analyses are used when coinheritance of alleles at a marker locus with a
disease is studied in a pedigree using families with two or more affected individuals and a
cytogenetic map. The linkage analyses can be made either as two-point (with one marker)
or as multipoint analyses (using several markers simultaneously). Also, the linkage can
be studied either as non-parametric where no genetic modelling is needed, or as
parametric with a supposed inheritance model. Here, the non-parametric linkage analyses
were made as multipoint (studies II, IV and V) and as two-point (study III) using the
computer package GENEHUNTER (Kruglyak et al. 1996; Daly et al. 1998).  The
qualitative traits were used for phenotypes: asthma/ unaffected, high (>100 kU/L)/ low
serum total IgE level (Burrows et al. 1989; Postma et al. 1995), and positive/ negative
allergy screening test result. Serum total IgE level was also analyzed as a quantitative
trait with the MAPMAKER/SIBS (studies II and IV).
3.5.2. Transmission disequilibrium test
In families with heterozygotic unaffected parents and an affected child the transmission
disequilibrium test (TDT) was performed. In the TDT, the transmitted
alleles/chromosomes to the affected child are compared with the untransmitted
alleles/chromosomes (Ewens and  Spielman 1995) of the parents. For the study III, the
TDT was also analyzed separately for paternal and maternal transmissions to sons and
daughters because of the different inheritance patterns of the two studied markers.
3.5.3. Allele and haplotype association analyses
In allele and haplotype association studies a chromosome was marked as ‘trait-
associated’ if it occurred in any of the affected family members and as a ‘control’ if it
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occurred only in unaffected individuals. Every chromosome in each family was counted
only once, and the unaffected family members formed the pool for control chromosomes
(Thomson 1995). In the study IV, another method for marking trait-associated
chromosomes was used to analyze dominant inheritance. A chromosome was marked as
‘trait-associated’ if it occurred in at least two affected family members, and again, as a
‘control’ if it occurred only in unaffected individuals. The haplotypes were constructed
by hand for the studies II, III and IV and by data mining for the study V. The significance
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independently, the nominal P values were multiplied by the number of tests (Bonferroni
correction).
3.5.4. Haplotype Pattern Mining method
In the Haplotype Pattern Mining (HPM) all trios with one or two affected individuals
were chosen for haplotype analyses. The trios were formed of larger pedigrees with an in-
house computer program which excluded trios having a member with an unknown
phenotype or an unknown genotype. The chromosomes were divided into ‘trait-
associated’ or into ‘controls’ as explained previously (see allele and haplotype
association) and in case of ambiguities, the alleles were zeroed out. Then, using
algorithms, the specific haplotype patterns associated with the trait were searched for.
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spanning across the marker and exceeding the set threshold for disease-association was
counted (a marker-wise score). The method relies on the assumption that there is more
linkage disequilibrium in the set of disease-associated chromosomes than in the set of
non-associated chromosomes in the proximity of a disease susceptibility allele. The
greater the difference in the levels of the linkage disequilibrium, the more significantly
disease associated patterns will be found.
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In addition to the association threshold, the maximum length of a pattern and the number
of gaps (missing data or genotyping errors) are also set as parameters. A haplotype
pattern matches the chromosome, if all of its non-gap alleles agree with the respective
alleles in the chromosome. The scores of different markers are not directly comparable,
since the marker densities and their information content vary. To compensate for this,
HPM uses randomization to obtain marker-wise P values that are comparable with each
other. At each randomization cycle, the disease association status of each haplotype is
assigned at random, keeping the total number of affected and unaffected haplotypes
constant, and the scores are recalculated. The P value for a given marker is the proportion
of iterations at which a score larger than or equivalent to the experimental pattern is
obtained. The disease susceptibility gene is most likely to lie in the proximity of the
marker with the lowest P value (Toivonen et al. 2000).
3.5.5. Homozygosity testing
If an autosomal or X-chromosomal allele is associated with a disease, the homozygosity
for the allele should associate with the disease even more strongly, which can be tested
by simulations. In the study III, the simulations for homozygosity testing (Psimul2) of the
X-chromosomal marker alleles were carried out with females only. All unrelated affected
females were considered, and their observed alleles were used for simulations. Then, in
each of 100,000 iterations, random pairs of these alleles were formed, and the number of
simulated homozygous chromosome pairs was counted. The iterations provided a
distribution for the number of expected homozygotes under the null hypothesis of no
excess homozygosity, treating the number of alleles as fixed. Finally, the observed
number of homozygotes was compared with this distribution to obtain the Psimul2 value.
3.5.6. Statistical significance estimations using a permutation test
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the association analysis the permutation test was done by simulating the results (P
simul1): The observed genotypes were used with the same number of trait-associated and
control chromosomes as in the real data, but the affectus status of the chromosomes was
randomized. This randomization was iterated 100 – 10.000, times and the permutation
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values of the most extreme association in actual and simulated data.
3.5.7. Power estimations
The power estimations were based on simulations and the estimations (Simul3) were
done by choosing a haplotype present at a frequency F (5%, 10%, 15% and 20%) among
the affected chromosomes. The association was then simulated with 10 000 iterations for
each F, and the power to detect association was measured by the fraction of the replicates
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4. RESULTS
4.1 Phenotyping results
4.1.1. Verification of self-reported asthma diagnosis
Altogether 1015 individuals took part in the study, 401 of these were confirmed to have
asthma (132 males and 269/67 % females), and 465 individuals were grouped as non-
asthmatic family members (239 males, 236 females) (Figure 3). 149 individuals (94 self-
reported asthma patients and 55 family members) could not be classified into either
group, and they were handled as having an unknown phenotype. The study population
comprised 253 families, of which 111 were multiplex families with two or more affected
family members. The population included also 139 sib pairs which could be divided into
50 sib pairs concordant with asthma and 28 control sib pairs, the rest being discordant
pairs (Figure 4). The verification of self-reported physician-diagnosed asthma was based
both on medical history and diagnostic lung function tests showing either reversible
airway obstruction or BHR or both using the criteria of the Social Insurance Institution
for reversible airway obstruction (Study I, Table 1). All the individuals were finally
categorized into asthma patients, controls (unaffected family members) or those with
unknown phenotype (Figure 3).
After the ascertainment, the obtained study population was carefully analysed to see if
self-reported physician-diagnosed asthma could be used as an inclusion criterium for
genetic studies. Self-reported asthma patients (N = 495) were divided into six diagnostic
categories (confirmed asthma, probable asthma, possible asthma, chronic obstructive
pulmonary disease, other causes for dyspnea) based on a review of medical records, and
those with insufficient data for classification formed the seventh group. In 364 patients
(73,5 %), self-reported asthma was confirmed, the results being based both on medical
history and diagnostic lung function tests showing either reversible airway obstruction,
BHR or both or who had reimbursement for anti-asthmatic medication granted by the
Social Insurance Institution (Table 5). The long-term smokers had been excluded from
this group. The group of probable asthma patients (N = 37; 7 %) included all the patients
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who reported recurrent asthmatic symptoms but who did not have a reimbursement for
medication. 54 % of these patients had a reversible airway obstruction shown in lung
function tests but either the disease history was too short for the reimbursement or the
data for the reimbursement was not found in medical records. 16 % of the patients with
probable asthma had bronchial hyperreactivity and had been auscultated with wheezings
but had not had diagnostic findings in spirometry, in PEF recording or in exercise test. 30
% of the patients with probable asthma had developed asthma in childhood and their lung
function tests were either insufficiently done or the documentation of the testing was poor
or inaccessible, or the results were not diagnostic according to our criteria. However, both
the group of confirmed and probable asthma patients represented those who reported a
constant need for medication and a positive response to medication. The groups of
confirmed asthma and probable asthma were included in our genetic studies with the
verified phenotype of asthma.
In the group of possible asthma patients (N = 26), some asthma symptoms and reversible
airway obstruction/BHR were found, but during the follow-up period found in the
medical records, neither recurrent symptoms nor a need for medication was developed. In
the group of patients with chronic obstructive pulmonary disease (COPD, N = 28), those
were included who had been smoking for over twenty years. The main component of
their disease was the irreversible obstruction of the airways developed at later age than in
verified asthma patients. Five patients had other causes of pulmonary insufficiency. All
these patients had dyspnea, but no clinical evidence of asthma. Seven patients had been
diagnosed with occupational asthma and were not considered suitable for a genetic study.
In 28 patients the medical records were either insufficient or not available for
classification. The groups of possible asthma and COPD patients as well as those with
other causes of pulmonary insufficiency or insufficient data for classification were
labelled as phenotype unknown (non-classified) in our genetic studies. Those with
occupational asthma were also labelled as phenotype unknown. In addition, those family
members that reported having asthma symptoms (dyspnea or wheezing) and having used
anti-asthmatic medication (N = 55) were classified as phenotype unknown.
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Table 5. Characteristics and lung function test results of the self-reported asthma patients
either with (A) or without (B) reimbursement for medication and who were verified to
have asthma. Those who were excluded from the asthma patients were classified as
having an unknown phenotype (C) and consisted of patients with mild asthma like
symptoms but no diagnostic finding in lung function tests, patients with COPD, patients
with other causes for dyspnea, patients with occupational asthma and patients with
insufficient data.
Verified asthma patients Phenotype
unknown
A. Reimbursement for
medication
B. No reimbursement
for medication  C.
N = 364 (%) N = 37 (%) N = 94 (%)
Male 120 (33) 12 (32) 32 (34)
Age, average (years) 43 *# 32 £ 47
S - IgE, average (kU/L) 237 389 331
Smoking regularly > 10 y 59 (16) # 3 (8) £ 39 (41)
Wheezing by auscultation 227 (62) *# 20 (54) 29 (31)
Average age at diagnosis (y) 35 # 28 £ 46
Diagnosis made in childhood 15 (4)* 11 (30) £ 2 (2)
Spirometry
Information available 307 (84) *# 21 (57) 55 (59)
Diagnostic results 174 (48) 11 (30) 36 (38)
PEF recording
Information available 312 (86) *# 26 (70) £ 47 (50)
Diagnostic results 197 (54) 14 (38) 30 (32)
Exercise testing
Information available 103 (29) # 10 (27) 15 (16)
Diagnostic results 29 (8) 3 (8) 2 (2)
Histamine or methacholine
challenge
Information available 229 (63) # 19 (51) 37 (39)
Diagnostic results 176 (48) # 16 (43) 22 (23)
Any of the above tests
Information available 325 (89) *# 27 (73) 58 (62)
Diagnostic results 280 (77) 20 (54) 46 (49)
* Statistically different results between the groups A and B.
#
 Statistically different results between the groups A and C.
£
 Statistically different results between the groups B and C.
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4.1.2. Allergy screening, serum total IgE and self-reported allergic symptoms
The serum total IgE level was measured of 1008 samples, and the cut-of-point for high
serum total IgE level was set to 100 ku/L (Burrows et al. 1989; Postma et al. 1995),
although in the clinical medicine the reference value of serum IgE for the Finnish adults
is <110 kU/L (Björksten et al 1987). There were 362 individuals (47% males) with a high
serum total IgE level and 646 (39% males) with a low IgE level, and the difference
between sexes was significant (p<0.02). 49% of the high responders had confirmed
asthma, while the respective number for the low responders was 35% (P<0.00002).
Smoking habits did not differ between the two groups. Those with a high serum total IgE
level, were 39.5 years old on average and those with a low level were significantly older,
46 years on average.
To see how well phenotypes of sib pairs correlated to each other, the serum total IgE
values of concordant sib pairs with asthma and the unaffected phenotype were compared.
The correlation for the IgE among the sib pairs concordant with asthma was 0.43 (95%
CI ± 0.17) and among sib pairs concordant with an unaffected asthma status 0.32 (95%
CI ± 0.23) (Figure 5).
16
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Figure 4. Number of concordant sib pairs with asthma, with a
low serum total IgE and with a high serum total IgE level.
Asthma
IgE > 100 kU/l IgE ≤ 100 kU/l
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When the characteristics of the allergy screening test positive (N=334) and negative
(N=672) individuals were studied, their sex did not have a significant effect (males 46 %
vs. 40 %, respectively) but the smoking habits were significantly different between the
positive and negative individuals (smoking for over 10 years, 16 % and 23 %
respectively), which was different from the high and low serum total IgE groups. As
expected, the allergy screening test positive individuals were significantly younger (33
years vs. 49 years, respectively), and the serum total IgE level was higher (420 kU/L vs.
72 kU/L, respectively) as well as the percentage of asthma patients was higher (52 % vs.
34 %, respectively) among the screening test positive individuals.
The distribution of specific IgE antibodies was also studied with the following
observation among all the study individuals: 17.5 % had specific IgE antibodies for cat,
17.0 for % timothy, 16.8 % for dog, 13.6 % for house dust mite, 12.6 % for birch, 11.6 %
for horse, 7.2 % for mugwort, and 3.9 % for mould Cladosporium herbarum. The
respective numbers for the verified asthma patients were: 28.4 % had specific IgE
antibodies for cat, 28.4 % for dog, 27.2 % for timothy, 20.4 % for horse, 19.2 % for birch,
17.2 % for house dust mite, 10.2 % for mugwort, and 6.5 % for mould cladosporium
herbarum. The spectrum of allergy antibodies among the asthma patients did not differ
from that found among the family members, but the screening positive asthma patients
had more frequently two or more specific antibodies elevated compared to their family
members.
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Figure 5. Logarithm of total serum IgE values in sib pairs concordant with the asthma
status: Asthma (E#"			!F "
For the whole study population, the screening results for IgE-mediated allergy were
compared to the self-reported nasal allergic symptoms and self-reported physician
diagnosed allergic rhinitis among the asthma patients and among their family members.
Neither of the questions reached a high sensitivity, specificity nor positive/ negative
predictive value. Among the self-reported asthma patients, 93 % of the allergy screening
positive but also 74 % of the screening negative, reported symptoms of allergic rhinitis
(Table 6). The corresponding figures among their family members were 61 % and 40 %,
respectively. Self-reported allergic symptoms showed a better sensitivity in both groups
(93 % for the asthma patients and 61 % for the family members) than a physician
diagnosed allergic rhinitis (68 % and 29 %, respectively), whereas a diagnosed allergic
rhinitis showed a better specificity (54 % among the asthma patients and 91 % among the
family members) than self-reported allergic symptoms (26 % and 60 %, respectively) in
both of the groups.
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4.2. Genotyping results according to chromosomal locations
4.2.1. Chromosomal region 5q31-q33 (Studies II and V)
 A large chromosomal area on chromosome 5q including a cytokine gene cluster has been
suggested to be involved in IgE production, eosinophilia and bronchial hyperractivity. In
Study II, 16 polymorphic markers were genotyped on the chromosome 5q31-q33
spanning 30 cM. The markers were genotyped in 313 individuals forming 157 families
with 73 sib pairs and 41 cousing pairs. Two phenotypes were analyzed as qualitative
traits (asthma vs. unaffected, and serum IgE >100 kU/L vs. serum IgE <100 kU/L), and
no linkage between asthma or high serum total IgE level was found. The NPL scores
were negative across the studied region. In Study V, the 5q31 region was reanalyzed in
79 families for asthma and in 45 families for high serum total IgE level using 12 SNPs in
addition to microsatellites. Again, asthma and high serum total IgE level were used as
phenotypes and analyzed as qualitative traits. The non-parametric linkage score (NPL)
was negative throughout the studied region for both phenotypes (information content
35%-69%).
In the allele association analysis where SNPs were also used (study V), no allele
association with asthma or high serum total IgE level could be detected. In the haplotype
association analysis (Study II) with microsatellites, some clustering of haplotypes around
the IL9 marker was found, but according to the permutation test the clustering was not
significant. Because of the concentration of the haplotypes around the IL9 marker in the
first study on 5q, the IL9 gene was sequenced in four individuals. A polymorphism
(338C>--.G"	
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IgE level.
The haplotype reanalysis of the 5q31 region with SNPs added to the microsatellites was
done with 299 disease-associated and 245 control chromosomes for asthma, and with 231
trait-associated and 177 control chromosomes for high serum total IgE level. The SNP
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haplotypes were made using an in-house computer program, and the same haplotypes
were used as an input for the Haplotype Pattern Mining. 30 % missing data but no errors
were allowed in the haplotype patterns. The majority of the asthma 5q31 haplotype
patterns spanned across the marker CSFenh2, but no pattern around the CSFenh2 was
significantly disease-associated. For high IgE, haplotype patterns around the SNP
IL13ex4.1 were found, but the chi square values were rather low.
The HPM analysis of the 5q31 cytokine cluster was done by setting the maximum length
of pattern for 5 markers, allowing one gap in the pattern (for missing data and possible
errors) and using the χ2 threshold 3.0 for association. The best obtained P value for
asthma was 0.3 (IL13ex4.1), 0.015 for high serum total IgE (IL13ex4.1) (Study V, Figure
1). To analyze the significance of the results, a permutation test with 1000 randomisation
of the affectus status of the chromosomes was performed. The permutation showed that
the best observed P values were between the 0.05 and 0.001 levels of the permutated
data. However, the marker-wise P values need a correction for multiple testing even after
the permutation. This correction is dependent on the number of studied phenotypes, the
number of studied markers and the number of studied HPM settings. The two correlated
phenotypes and the two different loci that have been studied form a correction factor of
2.6. Although the final number of the independent tests is difficult to determine, the best
obtained marker-wise P values do not tolerate much further correction.
4.2.2. The IL4RA gene on 16p12 (Study V)
On the chromosome 16p12 is located the IL4RA gene which codes the α chain of the
interleukin 4 receptor. In the linkage analysis of the study V, 79 families were analyzed
for asthma phenotype and 45 families for high serum total IgE level using 7 SNPs in the
IL4RA gene. No evidence for linkage was found in the IL4RA region for either of the
phenotypes with the NPL score from –1.4 to 0.1 (information content 53%-62%).
No allele association was found with asthma or high serum total IgE level with IL4RA
SNP alleles, when one affected individual was randomly selected from each family and
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compared to family based controls. The haplotype association was studied with 320
disease-associated and 260 control chromosomes for asthma and 257 trait-associated and
195 control chromosomes for high IgE level. Again, the haplotyping was done with the
in-house computer program. Both asthma- and high IgE -associated haplotype patterns
clustered around markers Sil676 and Sil1114, but the found associations were weak.
The HPM analysis of the IL4RA gene SNPs was done with the same settings as for 5q
(the maximum length of pattern for 5 markers, one gap in the pattern and the χ2 threshold
3.0). The best obtained P value in the IL4RA was 0.012 for asthma (S411L) and 0.019 for
high serum total IgE (C406R) (study V, Figure 1). The permutation test with 1000
randomisation showed that the best observed P values were between the 0.05 and 0.001
levels of the permutated data. According to the HPM results, the IL4RA as an asthma and
atopy susceptibility gene cannot be excluded in this population.
The allele combinations in IL4/IL4RA and IL13/IL4RA genes of each asthma patient
with a 2x2 contingency table were also studied. To avoid an ascertainment bias, only one
affected family member was randomly selected from each family. Since attained sample
size did not have statistical power to evaluate the significance of very rare combinations,
affected individuals who were homozygous for the minor alleles in both marker loci were
excluded. The only observation for asthma that differed from what was expected was the
distribution between IL13ex4.2 and Sil676 alleles (P<0.03). For high IgE, the distribution
between IL13ex4.2 and Sil676 alleles showed a similar weak association (P<0.04, data
not shown). However, the correction for multiple testing rendered these weak
associations insignificant.
4.2.3. The FCER2 gene region on 19p13 (Study IV)
The FCER2 gene for the low affinity receptor for IgE on chromosome 19 has been
suggested to be involved in IgE production by a negative feed-back. In the chromosomal
region 19p13 spanning a 10-cM region, 8 markers were screened for 124 families with 57
sibpairs and 35 cousin pairs. Linkage analysis was done with 51 pedigrees for asthma,
56
with 44 pedigrees for high serum total IgE level and for the phenotype of positive allergy-
screening result with 40 pedigrees. For asthma, the NPL score remained negative. For the
phenotypes of high serum total IgE level and positive allergy-screening test, the NPL
score was positive but not significant (<1) (information content 72-74%). The serum total
IgE level was also used as a quantitative trait for linkage analyses, but again, no linkage
was found.
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(70/285 disease associated chromosomes and 38/226 control chromosomes, P<0.03) but
after the correction for multiple testing, the association was not significant. When the
haplotypes were studied, the haplotype D19S567*16-FCER2*2-D19S534*7-D19S922*8
showed a 5-fold risk for asthma with 18/316 (5.7 %) disease-associated and 3/244 (1.2
%) control chromosomes. However, the permutation test showed no significance for the
results (in 1 163 permutations out of 10 000 the association results exceeded the
observed, P=0.12). The haplotype D19S120*3-D19S536*4-D19S216*4-D19S567*16-
FCER2*3-D19S534*7 was detected for the phenotype of high serum total IgE level in
11/255 (4.3 %) trait-associated and in 3/352 (0.9 %) control chromosomes, and for
positive allergy-screening in 15/246 (6.0 %) trait-associated and in 7/370 (1.9 %) control
chromosomes (relative risk 5.2 and 4.9, respectively). With the permutation test,
however, the haplotype association reached significance only for high serum total IgE
level, Psimul1=0.038 (for the positive allergy-screening Psimul1=0.19).
When the haplotype association analysis was done by limiting the disease-associated
chromosomes into those that were found at least in two affected individuals in a family,
the haplotype D19S567*16-FCER2*2-D19S534*7 was found in 12/49 (24.5 %) of the
disease-associated chromosomes for asthma. In the previous analysis the respective
numbers were 18/316 (5.7 %), P=8.3e10-6. The same haplotype was present in 3/244 (1.2
%) of the control chromosomes (P=1.1e10-11). Using the same method for the phenotype
of high IgE, the haplotype D19S216*4-D19S567*16-FCER2*3-D19S534*7 was not
significantly enriched in the trait-associated chromosomes 6/48 (12.5 %). In the previous
analysis the respective numbers were 24/255 (9.4 %, P=0.2) for the trait-associated
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chromosomes and 12/352 (3.4 %) for the control chromosomes. For the phenotype of the
positive allergy-screening, none of the haplotypes was enriched.
The FCER2 gene was sequenced in four affected individuals including a homozygote for
the D19S567*16-FCER2*2-D19S534*7-D19S922*8 haplotype, and also in one control
individual, but no coding polymorphisms were found.
4.2.4. IL9RA region on Xq/Yq PAR (Study III)
Near the IL9RA gene region, one pseudoautosomal marker and one X-chromosomal
marker were genotyped in the area of 400kb. The linkage was studied as a non-parametric
two-point in 84 families including 80 sib pairs and 62 cousin pairs for asthma and high
serum total IgE level. The NPL score remained negative for both markers and for both
phenotypes with an information content of 34%-46%, but it did not allow exclusion.
The TDT was first analyzed in all the families with an affected child and heterozygous
parents and then separately for paternal and maternal transmissions to sons and daughters.
The allele sDF2*10 was transmitted to 34 and untransmitted to 16 asthmatic offspring
(Pχ2 = 0.01). The allele sDF2*10 originated mainly from two X-chromosomal
haplotypes: sDF2*10-sDF1*6 (11 transmitted vs. 3 chromosomes untransmitted, Pχ2=
0.03) and sDF2*10-sDF1*1 (5 transmitted vs. 0 chromosomes untransmitted, Pχ2= 0.03),
while none of the Y chromosomes showed a transmission distortion. When studying
maternal transmission to affected daughters, the haplotype sDF2*10-sDF1*6 was
transmitted (5) more frequently to affected daughters than untransmitted (0), (Pχ2= 0.03).
For high serum IgE, the TDT results were not significant.
In the allele association analysis, the X-chromosomal allele sDF2*10 was found more
frequently in disease-associated (asthma) than in control chromosomes (28% vs. 20%,
Pχ2=0.05). In 176 permutations out of 1,000, the most extreme allele association found in
simulated data was stronger than in actual data (Psimul1=0.18). The allele frequencies of
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the marker sDF1, present both in X and Y chromosomes, were equally distributed in trait-
associated and control chromosomes. The haplotype association analysis was performed
on X chromosomes and for asthma, the haplotype sDF2*10-sDF1*6 was found more
frequently in disease-associated chromosomes than in control chromosomes (40 vs. 7,
Pχ2<0.005). The finding remained significant in the permutation test. In only 40 out of
1 000 iterations, the found haplotype association was more extreme than in actual data
(Psimul1=0.04).  Analyzed separately for male and female X chromosomes, the
association was significant for females (34 affected haplotypes and 6 controls, Pχ2<
0.05). For high IgE level, no allele or haplotype associations were found.
If an excess of homozygotes could be found, was next tested. The testing for the sDF2
alleles was done with unrelated females only in 100 000 simulations. In the testing, an
excess of homozygosity was found for the sDF2*10 allele and asthma phenotype but not
for other alleles and not for the marker sDF1. Among the asthma patients, 13 sDF2*10
homozygous individuals were observed, whereas the average, as expected from the
simulation, was 7.7 (Psimul2=0.009). For the controls, the number of homozygous
individuals was only 3. The overall observed homozygosity for both markers did not
differ from the expected homozygosity.
In this data set, our power to show haplotype association for high total serum IgE level
was high, if the frequency of a susceptibility haplotype among trait-associated
chromosomes (F) was between 0.15 and 0.20 (99% and 93%, respectively). When F=0.10
or F=0.05, the corresponding power to detect the association gradually decreases (67%,
and 18%, respectively). Our power to detect a haplotype association for the asthma
phenotype was similar: 97% (F=0.20), 81% (F=0.15), 49% (F=0.10), and 6% (F=0.05).
4.2.5. Cystic fibrosis mutations carriers and asthma (unpublished data)
The CFTR mutation carriership has both been reported to predispose individuals to
asthma (Dahl et al. 1998) and to protect them from asthma (Schroeder et al. 1995).
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detected in Finland (Kere et al. 1994), the possibility to screen for CFTR mutation
carriers in asthma families was unique. All unrelated individuals were selected from the
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the 166 asthma patients, four were carriers of the del394TT mutation whereas none of the
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found. The carrier frequency of the del394TT mutation was 1,9 % in this population
which was selected through a proband with asthma and which is located in the area with a
known clustering of Finnish cystic fibrosis patients.
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5. DISCUSSION
Our study population was designed to find major genetic regulators that would increase
the risk of the disease 3-5 fold. The simulations showed that in the haplotype association
analyses we had a good power to detect an excess of 20-15 % of the susceptibility
haplotypes. In these studies, we found evidence of the IL13 and IL4RA genes containing
susceptibility alleles as well as the FCER2 gene region and the IL9R region including
genetic asthma and atopy determinants in the Finnish population. In the previous studies
on candidate genes worldwide, the results have been controversial, and none of the genes
has been shown to be common for all studied populations. However, the 5q31 cytokine
gene cluster and especially the IL4 pathway with its receptor, have probably been the
most apparent finding, and our results are in agreement with others. Next, we shall
represent some aspects that have to be taken into consideration when our studies are
estimated.
5.1. Aspects of phenotyping
We confirmed the self-reported asthma diagnosis using retrospective data on medical
records with previously done lung function testing and clinical examination. This was
possible, because the diagnostic criteria for asthma in Finland are based on the
recommendation of the American Thoracic Society (ATS, 1987) and the criteria are
uniform in the whole country. Also, the reimbursement policy of the Finnish Social
Insurance Institution favours uniform diagnostic procedures: The reimbursement for anti-
asthmatic medication is granted only if the exact criteria are met. This procedure is to
guarantee that especially those patients who need regular medication are carefully
diagnosed, including the basic lung function testing before the medication is started. The
third beneficial factor was that most of the asthma patients had undergone the clinical
examination for asthma in the same clinic (Kainuu Central Hospital) which has employed
only few pulmonologists over the years. Thus, although we were not able to examine the
patients under the current study protocol, we were familiar with the used diagnostic
criteria, and we were able to trace back the diagnostic procedures in the medical records
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in most cases. Since then, diagnosing asthma on the basis of questionnaire data was
studied, and it was demonstrated that the questionnaire-based asthma diagnoses agree
well with those based on interviews, and that the pulmonary function testing added little
to questionnaires and interviews (Barnes et al. 1999). Also, a good agreement between
questionnaire data and medical records of other chronic diseases, such as cardiovascular
diseases and diabetes, has been shown in the Finnish study by Haapanen et al. (1997).
Since we verified the asthma diagnoses in medical records neither used the self-reported
data alone nor accepted those with long smoking history, we also rejected individuals
with other obstructive lung diseases and thus false positives (Los et al. 1999).
We used three phenotypes in these studies (asthma, high serum total IgE level and
positive allergy screening), two of them being especially overlapping. Bronchial
hyperreactivity (BHR) would have been an interesting subphenotype to use, but because
of the time and the method differences (both histamine and methacholine challenge had
been used) in the previously done bronchial hyperreactivity testing we found the BHR
problematic to study. Also, Finnish asthma patients are normally treated with inhaled
corticosteroids as soon as the diagnosis is obtained, and since inhaled corticosteroids are
known to reduce the BHR (Laitinen et al. 1991), the number of hyperreactive individuals
would probably been lower than during the diagnostic testing. However, it would have
been interesting to have a clinical examination of the probands to evaluate a more
detailed course of their disease. Also, if bronhial hyperreactivity should be used as a
phenotype in this population, retesting would be advisable both to avoid the previously
mentioned time and methodological differences and to offer a quantitative trait for
linkage analysis. Also, 11 % of the self-reported asthma patients were excluded because
of either insufficient data or negative test results. By having included a retesting of lung
functions in our study protocol, we might have been able to classify some of those as
confirmed asthma patients and thus to get more affected ones for our analyses.
We considered the granted reimbursement for anti-asthmatic medication as an objective
verification for asthma if long-term smoking was excluded and if there was no other
respiratory diseases.  However, in 11 % of those with confirmed asthma and
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reimbursement, the lung function test results were inaccessible for us. Thus, also in this
group the possibility to include the lung function testing in our study protocol would have
been valuable. The clinical course of asthma varies both between individuals and in the
same individual by time. The variation is both spontaneus and is affected by anti-
asthmatic treatment making the asthma diagnosis problematic. Having included lung
function testing in our study protocol would not have faded these problems but would
have offered current lung function test results for the diagnosis.
The unaffected family members did not undergo a clinical testing. Again, we chose to
accept the questionnaire information of asthmatic and allergic symptoms (or no
symptoms). Although allergic rhinitis and high serum total IgE are risk factors for asthma
in a population level (Burrows et al. 1989; Huovinen et al. 1999), there still are no tests
available that would point out those individuals actually getting symptomatic asthma. But
this is a general problem concerning studies of diseases with an additional adult-onset
phenotype. Also, if there are affected individuals among the unaffected ones, the results
of association analysis are diluted rather than strengthened. However, also in this study
group, the possibility to do lung function tests might have been beneficial, since 11 % of
the family members were excluded because of self-reported asthma symptoms. Some of
these might have been included into affected ones with lung function testing.
When taken together, we considered self-reported physician diagnosed asthma as an
appropriate inclusion criterium for a genetic study when combined with the information
in the medical records and the granted reimbursement for the anti-asthmatic medication
by the Social Insurance Institution. Furthermore, self-reported allergic nasal symptoms
and self-reported physician diagnosed rhinitis had both a poor specificity and a poor
sensitivity, and these were not used without a verification of allergy, such as serum total
IgE level or allergy screening test.
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5.2 Choice of population
Isolated populations have been considered to be more advantegous than outbred
populations when studying multifactorial disorders because of the smaller number of
susceptibility alleles/genes as well as because of longer genetic intervals of linkage
disequilibrium. However, the number of founders or the genetic bottleneck needs to be
small (Kruglyak 1999) when using linkage disequilibrium based methods. In Kainuu, the
number of unrelated founding chromosomes has been estimated to be only a few
hundred. Also, during the first 200-250 years, the population remained small (a long and
narrow genetic bottleneck), after that the population rapidly increased to reach the current
size (Koskinen et al. 1994). Within the Kainuu population, the LD of those individuals
with a rare inherited disorder has previously been shown to extend up to 12 cM (Höglund
et al. 1995). Kruglyak et al. estimated the LD extent by simulations to be up to 3 kb in the
general population and that the extent of LD in isolated populations would not differ
significantly from that unless the number of founders was very low.
In other multifactorial diseases studied in Finland, promising results have been obtained:
Familial combined hyperlipidemia has been linked to the chromosomal area 1q21-q23
with a lod score of 5.9, but no specific haplotype was found (a study population
ascertained from several places across the country). For the psoriasis, a haplotype
spanning across two genes in the HLA area was found to be associated with the disease
(study population from the Kainuu region). In a genomewide search for the
schizophrenia, four loci with lod scores from 1.95 to 3.82 were detected (Kuusamo,
another isolated Finnish subpopulation) and in a genome scan of multiple sclerosis the
chromosomal area 17q22-q24 was found with a lod score of 2.8 (study population mainly
from the province of Vaasa). In the studies of the backround LD in a random Finnish
population and in a subpopulation of Finland (Kuusamo) Varilo et al. found only little
more LD in the Kuusamo population than in the general Finnish population (Varilo et al.
2000). This, however, does not mean that LD would not exist also in common diseases in
the disease-associated chromosomes around the disease causing gene, as shown in the
study of BRCA1 and BRCA2 carriers (Sarantaus et al 2000). Besides, as stated by Varilo
et al., a more uniform environment with the same culture and genome backround makes
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isolates better when phenotype-genotype correlations are assessed. Thus, we found the
Kainuu population optimal for susceptibility gene studies for asthma and atopy, although
the Finnish population as a whole would already have been too diverse for this study
design.
Although we considered that an isolated population would offer advantages in gene
mapping, it still may as well provide disadvantage. A susceptibility gene found in an
isolate may not be so important for genetic susceptibility in a more outbred population.
And even more probable is that not all those susceptibility genes found in a mixed
population will also be present in a founder population. Large populations likewise
include more affected individuals than small populations, which makes it easier to
achieve an adequate number of affected individuals for a genetic study. Additionally, it is
more difficult to obtain another population sample for the replication of the analysis in an
isolated and rather small population than in a large mixed population. A replication study
may be used to test if the found association between an allele/haplotype and a trait is
achieved by a chance or if it is a true association.
5.3. Power for linkage
The linkage analysis measures coinheritance of alleles at a marker locus with a disease in
families. It is measured by recombinations between a disease locus and a studied marker,
using a logarithm of odds score. In this type of analyses, large pedigrees with many
affected individuals are optimal. The linkage analysis is an especially suitable method for
rare inherited diseases where the inheritance pattern is known, the phenotype has a clear
cut-off point, the susceptibility alleles are rare in the common population and the number
of needed pedigrees is relatively small. Having negative linkage results despite of the
positive association results for the IL13, IL4RA, the IL9R gene region and the FCER2
gene region can be explained by a study population consisting of mainly nuclear families,
phenocopies in the same pedigree, low penetrance of the studied allele and genetic
heterogeneity (same phenotype may result from different genotypes) (Lander and Schork
1994). Even if genetic homogeneity could be achieved by choosing a founder for the
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study population, nevertheless, the low penetrance cannot be excluded as a possible
explanation for the negative linkage results.
The transmission disequilibrium test measures the possibility if a specific allele or
haplotype is more often transmitted to an affected individual than to an unaffected
individual in a family (transmission distortion). Thus, it is a combination of the linkage
and allele association approach. With trios, where one of the parents could also be
affected, our study population was designed for the haplotype association, and out of this
reason the sample size for the TDT was rather low, and it was not an optimal statistical
method for analyzing the results.
5.4. Association studies
The association analysis is a method for studying an association between a disorder and a
specific allele or a haplotype. An allele association analysis can be made either by using a
case-control approach or by using a family-based population strategy. The allele
association studies represented here are made by the latter method which is optimal,
when false positive results raising from the population stratification are wished to be
avoided (Lander and Schork 1994). The probability to find an association is also affected
by the dilution of control individuals with affected individuals, which would, however,
rather weaken than strengthen the results. Still, when association analyses have been
compared to linkage analyses, it was estimated that mapping complex diseases using
association based methods might require considerably less families compared with the
method of linkage analyses (Risch and Merikangas 1996).
The allele and haplotype associations, however, are not sufficient without a permutation
test which is used to correct the results for multiple testing. If the finished tests are
independent of each other, a simple Bonferroni correction may be used by multiplying
the obtained P-value with the number of accomplished tests. In association studies, the
number of tests that have been carried out is dependent on the number of tested loci, on
the number of used markers and on the number of obtained alleles/haplotypes as well as
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on the number of tested phenotypes. Since many of these variables are correlated with
each other, the effective number of independent tests is often difficult to determine. Thus,
in these situations, a permutation test may be more valid than a Bonferroni correction of
the results for multiple testing. A permutation test is done by randomizing the results: For
example, the real genotyping results are used with the same number of affected and
control chromosomes as in the real data, but the affectus status of the chromosomes is
randomized. A randomization of 100 – 10.000 times can provide information for results
that can be expected by chance and for results that might be considered significant.
Our study population with mainly nuclear families was designed to have an optimal
power for haplotype analysis, and we found evidence for the FCER2 gene region and for
the IL9RA gene region associating with high serum total IgE level and asthma. In the
FCER2 gene region, the haplotype  D19S120*3-D19S536*4-D19S212*4-D19S567*16-
FCER2*3-D19S534*7 associated with high serum total IgE level (Psimul1=0.038) and in
the IL9RA gene region, the haplotype sDF2*10-sDF1*6 associated with asthma.
However, for both the FCER2 and the IL9RA gene regions, the simulated P values
showed only borderline significance which raises the question of the biological
significance of the results. The weak allele associations (D19S922*8 and sDF2*10) did
not remain significant after permutation tests. Furthermore, the sequencing of the FCER2
gene did not reveal any polymorphisms. For the FCER2 gene region, some other still
unknown gene or regulatory element affecting the expression or function of the FCER2
gene might explain the positive haplotype association results, since no variations were
found. For the Xq/YqPAR region, the IL9RA gene is the obvious candidate because of
the immediate localization, but since we have neither used an intragenic marker nor
sequenced the gene, our evidence for the association to IL9RA is only partial. This is,
however, supported by the results of another study reporting linkage between the region
and bronchial hyperreactivity (Holroyd et al. 1998).
The carriers of the mutations of CFTR gene 1,9 % did not differ significantly from what
was expected to be the frequency of carriers, calculated by the incidence of cystic fibrosis
in the whole of Finland, although the mutations were enriched in Kainuu. Also, as
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expected by the previous studies on the geographical distribution of the two Finnish main
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mutation (Kere et al. 1994). Because of the low frequency of the CFTR mutation carriers
in the study population, the results of the CFTR mutation carriers and asthma were not
statistically significant. However, being very rare, the CFTR mutation cannot be a major
genetic regulator for asthma in Finland.
In the reanalysis of the 5q31-q33 with SNPs in addition to microsatellites, we used the
Haplotype Pattern Mining which is an another method for haplotype association analysis
and an application of data mining methods (Toivonen et al. 2000). By allowing gaps in
haplotype patterns, it is also more robust in case of genotyping errors and missing data
than the haplotype analysis we have used in our other studies. Also, the HPM parameters
can be optimized for each data set by studying the individual features of genotype data
such as marker information, marker density, and missing genotypes. With the HPM
method, we obtained evidence for the IL13 gene contribution to atopy (the best P value
0.015 for high serum total IgE with IL13ex4.1) and also for the IL4RA gene contribution
to asthma (the best P value with S411L was 0.012 for asthma, and with C406R 0.019 for
high serum total IgE). The association of IL13 gene polymorphisms with serum total IgE
level has previously been detected (Heinzmann et al. 2000, Graves et al. 2000) as well as
the association of IL4RA polymorphisms with asthma and atopy (Hershey et al. 1997;
Shirakawa et al. 1994; Ober et al. 2000). The evidence for these and many other studies
on the IL4 pathway contribution to atopy has been so convincing that it has led to clinical
studies with a soluble IL4 receptor (Borish et al. 1999). Still, more studies are needed to
get more experience from applications of the HPM method in haplotype and allele
analyses as well. Also, in these studies we have not tested functional consequences of the
IL13ex4.1 polymorphism, although the IL13 has previously been shown to be an
important molecule in the animal model of asthma (Grünig et al. 1998). In the IL4RA
gene, the polymorphisms associating with asthma and atopy were different (S411L,
C406R) and as far as these polymorphisms in this population are concerned, evidence for
functional changes is still missing.
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6. Summary and conclusions
Asthma is the third most common chronic disease in Finland considering the number of
individuals entitled to the reimbursement for medication or where the costs of refunded
medicines are considered (Finnish Statistics on Medicines, 1996). During recent decades,
the prevalence of atopy and asthma has increased, thus setting more people into an urgent
requirement for medication, although the clinical picture of the disorders has
simultaneously changed from severe into mild-moderate (Report of a Working Group
1996). Lower rates for infectious diseases and other environmental factors have been
suggested as the cause for the increasing prevalence.
According to the twin and family studies, there is a clear familial aggregation of atopic
disorders and estimations of genetic effect on asthma have varied from 35% to 87%. With
this study, we wished to investigate the candidate gene regions in asthma and atopy in the
Finnish population. This population was chosen because of the population history and
because of the previous molecular genetic findings that have revealed the isolated
character of the population. When susceptibility genes in complex disorders are mapped,
these kind of founder populations have been considered to be optimal (Wright et al.
1999).
The phenotyping was carried out with questionnaires, interviews, an evaluation of the
medical records with patients’ permission and serum total IgE and allergy screening test
measurements. The unaffected family-members were screened for atopic and asthmatic
symptoms with questionnaires and serum total IgE and allergy screening test
measurements. Self-reported physician-diagnosed asthma was compared to the data
obtained in medical records and self-reported allergic symptoms were compared to
allergy screening test results. We obtained the most accurate results in phenotyping by
combining the self-reported physician diagnosed asthma with the information in the
medical records and the granted reimbursement for the anti-asthmatic medication by the
Social Insurance Institution. The questionnaire based data has also been confirmed as
satisfactory for genetic studies by others (Barnes et al. 1999). However, if bronchial
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hyperreactivity should be used as a phenotype, retesting would be beneficial to achieve
current and accurate quantitative data. As to the allergies, because of the poor sensitivity
and specificity of the self-reported allergic nasal symptoms and of the physician-
diagnosed allergic rhinitis, we found objective verification of allergy (high serum total
IgE level or positive allergy screening test) necessary.
The genetic susceptibility to asthma and atopy was studied on chromosomal regions
5q31-q33, 16p12 (the IL4RA gene), 19p13 (the FCER2 gene region) and Xq/YqPAR (the
IL9RA gene region) using linkage and association analyses. Also the CFTR gene was
screened for two Finnish major mutations. All the linkage analyses remained negative,
but evidence was found for the FCER2 gene region and Xq/YqPAR contribution to atopy
and asthma with haplotype association analyses. On the chromosome 19p13, a six-marker
haplotype was found to be associated with high serum total IgE level and on chromosome
Xq, a two-marker haplotype was shown to be associated with asthma. Moreover, with the
Haplotype Pattern Mining method, the SNP IL13ex4.1 was shown to be associated with
high serum total IgE level, and in the IL4RA gene, S411L was shown to be associated
with asthma and, respectively, C406R with high IgE level. Because of the low frequency
of the CFTR mutations, no conclusions could be made for the association between the
CFTR mutation carriership and asthma.
The IL13 and IL4RA gene contribution in asthma and atopy has also been suggested in
other studies on both humans (Heinzmann et al. 2000; Ober et al. 2000) and mice (Grünig
et al. 1998), and our findings are in agreement with others and thus emphasized. Also, the
Xq/YqPAR with the candidate gene IL9RA has previously been linked to asthma
(Holroyd et al. 1998), and our findings of the halotype association with asthma support
the former results again underlining the importance of the IL9 pathway. The association
of the FCER2 region with high serum total IgE level was a novel discovery, but since the
sequencing of the FCER2 gene did not reveal any variations, the chromosomal region
needs to be studied further.
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Although several candidate gene studies on atopy and asthma as well as eight
genomewide searches have been done in different human populations during the recent
years, there still is no functional and well-established evidence for any of the genes
affecting genetic susceptibility to atopy and asthma. However, some molecules have been
demonstrated to be especially important in IgE mediated disorders, and these results have
led to clinical studies. Future studies will show whether the molecules of the IL4, IL9 or
IL13 pathway or antagonists for the low affinity receptor of IgE or any other studied
molecules are applicable for diagnostic use or for medication.
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